1Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vaneomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods [J]. Antimicrob Agents Chemother, 2003, 47 (10): 3040-3045.
2Sakoulas G, Gold HS, Cohen RA, et aI. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia [J]. J Antimicrob Chemother, 2006, 57 (4): 699-704.
3Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK [J]. J Antimicrob Chemother, 2006, 57 (4): 589-608.
4Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists [J]. Clin Infect Dis, 2009, 49 (3): 325-327.
5Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vaneomycin in patients with various degrees of renal function[J]. Antimicrob Agents Chemother, 1984, 25 (4): 433-437.
6Murphy JE, GiUespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters [J]. Am J Health Syst Pharm, 2006, 63 (23): 2365-2370.
7Sheiner LB, Beal SL. Some suggestions for measuring predictive performance [J]. J Pharmacokinet Biopharm, 1981, 9 (4): 503-512.
8Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin [J]. Clin Infect Dis, 2006, 42 (Suppl 1): S35-39.
9Burton ME, Gentle DL, Vasko MR. Evaluation of a Bayesian method for predicting vancomycin dosing [J]. DICP, 1989,23 (4): 294-300.
10Rodvold KA, Blum RA, Fischer JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function [J]. Antimicrob Agents Chemother, 1988, 32 (6): 848-852.
